Technological Innovations in Behavioral Treatments for Cigarette Smoking

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Jesse Dallery, National Development and Research Institutes, Inc.
ClinicalTrials.gov Identifier:
NCT00926939
First received: June 23, 2009
Last updated: October 15, 2013
Last verified: October 2013

June 23, 2009
October 15, 2013
June 2009
February 2014   (final data collection date for primary outcome measure)
  • CO sample of ≤ 4ppm [ Time Frame: 4 weeks, 7 weeks during intervention; 3 months and 6 months after intervention ] [ Designated as safety issue: No ]
  • Participant reporting not smoking, not even a puff in the last 7 days. [ Time Frame: 4 weeks, 7 weeks during intervention; 3 months and 6 months after intervention ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00926939 on ClinicalTrials.gov Archive Site
  • Twice-daily breath CO samples obtained during treatment period. [ Time Frame: First 4 weeks of treatment ] [ Designated as safety issue: No ]
  • The longest duration of sustained abstinence based on the twice-daily breath samples during the treatment period. [ Time Frame: First 4 weeks of treatment ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Technological Innovations in Behavioral Treatments for Cigarette Smoking
Technological Innovations in Behavioral Treatments for Cigarette Smoking

The purpose of the study is to evaluate a sustainable and broadly accessible treatment delivery model (Motiv8) for smoking cessation based on abstinence-reinforcement.

Smokers are randomly assigned to one of two groups: an Abstinence Contingent (AC) group and a Submission Contingent (SC) group. The AC group receives vouchers for abstaining from smoking (measured by a carbon monoxide monitor and confirmed through video-submission), and the SC group receives vouchers for submitting videos of their carbon monoxide breath tests. Both groups take videos of their CO-monitoring on a secure website designed for the study, as well as receive standard care counseling and education related to smoking cessation. The main intervention lasts four weeks, and a three-week maintenance phase will follow. Assessments will be conducted at intake, week four (end of the main treatment phase), and at three and six months after the intervention period is completed

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Caregiver)
Primary Purpose: Treatment
Cigarette Smoking
  • Behavioral: Reinforcement for the abstinence of smoking
    Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
  • Behavioral: Reinforcement for submission of videos with CO sample
    This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
  • Experimental: Abstinence Contingent (AC)
    This group will receive vouchers contingent on smoking reduction and smoking abstinence (confirmed through video submissions). Abstinence is defined as a CO sample of 4ppm or less.
    Intervention: Behavioral: Reinforcement for the abstinence of smoking
  • Experimental: Submission Contingent (SC)
    This group receives vouchers for submitting videos of their CO breath test.
    Intervention: Behavioral: Reinforcement for submission of videos with CO sample
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
100
May 2014
February 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Self-reported smoker
  • Permission to contact applicant by phone
  • Ability to use the internet

Exclusion Criteria:

  • Self-report of a history of or current severe or unstable medical or psychiatric illness that would interfere with the study
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00926939
R01DA023469, R01DA023469
No
Jesse Dallery, National Development and Research Institutes, Inc.
National Development and Research Institutes, Inc.
National Institute on Drug Abuse (NIDA)
Principal Investigator: Jesse Dallery, PhD National Development and Research Institutes, Inc.
National Development and Research Institutes, Inc.
October 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP